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Cardiovascular diseases (CVDs) are among the leading causes of morbidity and mortality
in both the developed and developing world. Rhizoma coptidis (RC), known as Huang
Lian in China, is the dried rhizome of medicinal plants from the family Ranunculaceae,
such as Coptis chinensis Franch, C. deltoidea C.Y. Cheng et Hsiao, and C. teeta Wall
which has been used by Chinese medicinal physicians for more than 2000 years.
In China, RC is a common component in traditional medicines used to treat CVD
associated problems including obesity, diabetes mellitus, hyperlipidemia, hyperglycemia
and disorders of lipid metabolism. In recent years, numerous scientific studies have
sought to investigate the biological properties of RC to provide scientific evidence for
its traditional medical uses. RC has been found to exert significant beneficial effects on
major risk factors for CVDs including anti-atherosclerotic effect, lipid-lowering effect, anti-
obesity effect and anti-hepatic steatosis effect. It also has myocardioprotective effect
as it provides protection from myocardial ischemia-reperfusion injury. These properties
have been attributed to the presence of bioactive compounds contained in RC such as
berberine, coptisine, palmatine, epiberberine, jatrorrhizine, and magnoflorine; all of which
have been demonstrated to have cardioprotective effects on the various parameters
contributing to the occurrence of CVD through a variety of pathways. The evidence
available in the published literature indicates that RC is a herb with tremendous potential
to reduce the risks of CVDs, and this review aims to summarize the cardioprotective
properties of RC with reference to the published literature which overall indicates that RC
is a herb with remarkable potential to reduce the risks and damage caused by CVDs.
Keywords: coptis root, Huang Lian, Coptis chinensis Franch, cardiovascular diseases, ethnopharmacology
INTRODUCTION
Cardiovascular diseases (CVDs) appears set to continue as the largest cause of death and disease
burden across the globe. They include a wide spectrum of life-threatening disorders such as
coronary heart disease (CHD), cerebrovascular disease and peripheral arterial disease, all of which
result from impairment to the heart and blood vessels (Wallace, 2011). Among the risk factors
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strongly associated with these disorders are high levels of low-
density lipoprotein (LDL) cholesterol, hypertension, diabetes,
and abdominal obesity (Walden and Tomlinson, 2011).
Rhizoma coptidis (RC), known as Huang Lian in China,
is the dried rhizome of medicinal plants from the family
Ranunculaceae, including Coptis chinensis Franch, C. deltoidea
C.Y. Cheng et Hsiao, and C. teeta Wall (Chen et al., 2008; Ma
et al., 2012). It is a well-known herb in traditional Chinese
medicine and has a long history with its pharmacological uses
first mentioned in the Shen Nong Ben Cao Jing (a compilation
of information regarding Chinese herbs dating back to 2800 BC)
in the Eastern Han Dynasty (Yi et al., 2013). Ancient beliefs state
that it is “cold” in nature and is able to remove damp heat, fire
or toxicity (Wang et al., 2014). For over 2000 years, Chinese
medicinal physicians have used RC as a food additive and herbal
medicine for its antibacterial, antiviral, anti-inflammatory, anti-
hyperglycemic and hypolipidemic activities (Kou et al., 2016).
Today, RC is still widely utilized in herbal medicine for the
treatment of various conditions. This is evident based on a
survey of patented medicines in China which reveals that RC
is commonly used as one of the ingredients in preparations to
treat obesity, diabetes mellitus, hyperlipidemia, hyperglycemia
and lipid metabolism disorders (Chen, 2009; Ye et al., 2009; Guo,
2012; Li et al., 2015; Wang, 2015). Given the potential benefits in
seeking new approaches to treating and preventing CVDs, there
has been tremendous interest among the scientific community in
exploring the biological properties of RC and providing scientific
evidence for its traditional medical uses. At the same time,
it is also crucial to investigate the phytoconstituents that are
Abbreviations: ACC, acetyl coenzyme A carboxylase; ADP, adenosine
monophosphate; AMPK, adenosine 5′-monophosphate (AMP)-activated protein
kinase; AP-1, activator protein 1; ASBT, apical sodium-dependent bile salt
transporter; ATP, adenosine triphosphate; Bax, Bcl-2-associated X protein; Bcl-2,
B cell lymphoma 2; BNIP3, BCL2/adenovirus E1B 19kDa interacting protein 3;
C/EBP-α, CCAAT/enhancer-binding protein- α; CK, creatine kinase; COX-2,
cyclooxygenase-2; CPT1α, carnitine palmitoyl transferase 1-alpha; cTn1, cardiac
troponin I; CYP7A1, cholesterol 7-alpha-hydroxylase; EMMPRIN, extracellular
matrix metalloproteinase inducer; eNOS, endothelial nitric oxide synthase;
FAS, fatty acid synthase; FXR, farnesoid X receptor; GSK3β, glycogen synthase
kinase 3β; HDL, high density lipoprotein; HDL-c, high density lipoprotein
cholesterol; Hes1, Hairy and enhancer of split 1; HMG-CoA, 3-hydroxy-
3methylglutary-CoA; HMGCR, 3-Hydroxy-3-methylglutaryl CoA reductase;
HO-1, heme-oxygenase-1; HUVECs, human umbilical vein endothelial cells; IL,
Interleukin; I/R, ischemia/reperfusion; iNOS, inducible nitric oxide synthase;
JAK, Janus kinase; JNK, c-Jun N-terminal kinase; LDH, lactate dehydrogenase;
LDL, low density lipoprotein; LDL-c, low density lipoprotein cholesterol; LDLR,
low-density lipoprotein receptor; LPS, Lipopolysaccharide; LXR, liver X receptor;
MAPK, p38 mitogen-activated protein kinase; MCP-1, monocyte chemoattractant
protein-1; MDA, malondialdehyde; MMP, matrix metalloproteinase; mTORC2,
mammalian target of rapamycin complex 1; NFκB, Nuclear factor-kappaB;
Ox-LDL, oxidized low density lipoprotein; pACC, phosphorylated-ACC; PGC1α,
peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PI3K,
phosphoinositide 3-kinase; PMA, phorbol 12-myristate 13-acetate; PPAR,
proliferator-activated receptor; PTEN, Phosphatase and tensin homolog deleted
on chromosome 10; ROCK, Rho-kinase; ROS, reactive oxygen species; SIRT1,
Sirtuin 1; SOD, superoxide dismutase; SREBP2, Sterol regulatory element binding
transcription factor 2; STAT3, signal transducer and activator of transcription 3;
TBA, total bile acids; TBARS, thiobarbituric acid reactive substances; TC, total
cholesterol; TG, triglyceride; TGR5, G-protein coupled bile acid receptor; TLR4,
toll-like receptor 4; TNF, tumor necrosis factor; TXNIP, thioredoxin-interacting
protein; UCP 2, uncoupling protein 2; VMSCs, vascular smooth muscle cells.
responsible for the biological properties (Moghadamtousi et al.,
2013; Tan et al., 2015). Based on current knowledge, the major
bioactive compounds contributing to RC’s bioactive properties
are berberine, coptisine, palmatine, epiberberine, jatorrhizine
and magnoflorine, as illustrated in Figure 1 (Hung et al., 2007a;
Kou et al., 2016). There is a large of body of work suggesting that
RC has protective properties against several major risk factors
and damage caused by CVDs. This review aims to summarize the
currently available evidence of RC’s cardioprotective properties—
both in vitro and in vivo studies were included and are
summarized in Table 1.
CARDIOPROTECTIVE ACTIVITIES OF
RHIZOMA COPTIDIS
Anti-Atherosclerotic Effect
Atherosclerosis is one of the most important causative factors of
certain CVDs such as myocardial infarction (MI), heart failure,
stroke and claudication (Frostegård, 2013). Atherosclerosis refers
to a specific form of arteriosclerosis in which an artery-wall
thickens due to invasion and accumulation of lipid laden
white blood cells (foam cells) and proliferation of intimal-
smooth-muscle cell forming a fibrofatty plaque (Lucas and
Greaves, 2001). There have also been studies supporting the
anti-atherosclerotic effects of RC. For example, a study on
the anti-atherosclerotic potential of Ger-Gen-Chyn-Lian-Tang (a
traditional mixture which contains berberine as one of its major
active components) has demonstrated reduced atherosclerotic
lesions and collagen expression within the atheroma plaques in
mice. In addition, in vitro work has also shown a reduction in
migration of vascular smooth muscle cells, which is significant as
pathological migration of these cells represents a key step in the
pathogenesis of atherosclerosis (Ho et al., 2012).
Reactive oxygen species (ROS) play a crucial role in the
development and progression of atherosclerotic lesions because
the formations of lesions are related to several ROS-regulated
events. It was found that uncoupling protein 2 (UCP-2), the
mitochondrial inner membrane protein can provide antioxidant
mediated defense by negatively regulating ROS production
(Moukdar et al., 2009). Utilizing a mouse model, Wang et al.
(2011) reported that chronic administration of berberine resulted
in significant reduction of aortic lesions, diminished oxidative
stress and lowered expression of adhesion molecules in the aorta;
this anti-atherogenic activity was due to AMPK-dependent ROS
suppression through enhanced expression of UCP-2. Oxidative
modification of LDL is also believed to be one of the main risk
factors leading to atherosclerosis (Itabe, 2009); berberine—one
of the major bioactive components of RC—has been reported to
inhibit oxidation of LDL by virtue of its significant antioxidant
activity (Hsieh et al., 2007). Berberine also appears to protect
against oxidized-LDL induced apoptosis as demonstrated by
reduced levels of mitochondrial cytochrome C, cleaved apoptotic
effectors, caspase 3 and poly(ADP-ribose) polymerase in human
umbilical vein endothelial cells treated with this compound
(Hsieh et al., 2007). Magnoflorine, another alkaloid isolated from
RC extract also possesses similarly beneficial effects; an effective
antioxidant, it prevents the oxidation of various forms of LDL,
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FIGURE 1 | Rhizoma coptidis which contains alkaloids such as berberine, coptisine, palmatine, epiberberine, jatrorrhizine and magnoflorine exerts
cardioprotective activity through its anti-atherosclerotic effect, protection from myocardial ischemia-reperfusion injury, lipid-lowering effect,
anti-obesity effect and anti-hepatic steatosis effect.
including native, glycated and glycoxidated LDL (Hung et al.,
2007a). Aside from this, magnoflorine also significantly inhibits
Cu2+ and thermo-labile radical initiator (AAPH)-induced lipid
peroxidation of high density lipoprotein (HDL); thus resulting in
HDL retaining its ability to protect LDL from oxidation (Hung
et al., 2007b).
Chronic inflammatory processes are a key additional factor
leading to the development of atherosclerotic lesions in the
vessel wall (Remppis et al., 2010). Hence, substances with
anti-inflammatory property may have the potential to prevent
atherosclerosis. Remppis et al. (2010) studied the effect of
RC extract and berberine on lipopolysaccharide (LPS)-induced
inflammatory activity in a murine macrophage cell line.
The results of this study demonstrated that RC extract and
berberine inhibit the production of monocyte chemoattractant
protein 1 (MCP-1/CCL2) in macrophages, likely via inhibition
of the transcription factors activator protein 1 (AP-1) and
nuclear factor-kappaB (NFκB). Coptisine, another of the
bioactive compounds in RC, also possesses demonstrable anti-
inflammatory property. It resulted in decreased nitric oxide (NO)
production in LPS-stimulated macrophages via inhibited protein
and mRNA expression of inducible nitro oxide synthase (iNOS);
additionally, the expression of pro-inflammatory cytokines
interleukin (IL)-1β and IL-6 was inhibited at transcriptional level.
The proposed underlying mechanism for these observations
was blockade of NFκB, mitogen-activated protein kinases
(MAPK), and phosphoinositide-3-kinase (PI3K)/Akt activation,
which are the intracellular inflammation signaling pathways in
macrophages (Supriady et al., 2015; Wu et al., 2016).
The accumulation of lipid-laden foam cells is also an
important step in the progression of atherosclerosis (Chi et al.,
2014). The authors demonstrated that berberine effectively
inhibited oxidized-LDL-induced foam cell formation through
the activation of adenosine 5′-monophosphate-activated protein
kinase (AMPK)-sirtuin 1-peroxisome proliferator-activated
receptor gamma (PPAR-γ) pathway as well as through reduced
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uptake of oxidized LDL by foam cells. Furthermore, the same
study showed that combination therapy of berberine and
atorvastatin (a well-established anti-atherosclerotic drug) was
more effective in preventing atherosclerotic processes compared
to administration of atorvastatin alone.
Clinically, the major concern when artherosclerosis is
present is the occurrence of plaque disruption which
may then lead to unstable angina, or an outright MI.
Plaque progression and destabilization is due to the over-
expression of matrix metalloproteinases-9 (MMP-9) and
extracellular matrix metalloproteinase inducer (EMMPRIN) in
monocytes/macrophages (Cao et al., 2014). Berberine inhibits
the up-regulation of MMP-9 and EMMPRIN in phorbol 12-
myristate 13-acetate-induced macrophages by suppressing
the activation of p38 pathway, showing its ability to stabilize
atherosclerotic plaque (Huang et al., 2011).
RC seems to have multiple active components that target
varying stages of the development of atherosclerosis through
a variety of pathways, thus making it an effective anti-
atherosclerotic agent.
Lipid-Lowering Effect
Hyperlipidemia or dyslipidemia, which is characterized by
increased plasma triglyceride concentration and lowered HDL
cholesterol, is one of the major risk factor contributing to the
progression of CVDs such as CHD and peripheral artery disease.
Hence, maintenance of total cholesterol (TC) level within the
normal range can be an effective strategy to lower the risk
of cardiovascular events (Zou et al., 2016). The liver is the
main site of cholesterol homeostasis maintenance, which involves
several distinct processes including biosynthesis via the activity of
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR),
uptake by low density lipoprotein receptors (LDLR), release of
lipoprotein in the blood, storage, degradation and conversion
into bile acids (Trapani et al., 2012). RC possesses lipid-lowering
effects as shown by the lowered cholesterol levels in different
animal models treated with RC extract (Yokozawa et al., 2003;
Cao et al., 2012; Kou et al., 2016). Studies have indicated
that the five main bioactive compounds in RC (berberine,
coptisine, palmatine, epiberberine, and jatrorrhizine) exert their
lipid-lowering effects through distinct mechanisms. Berberine’s
hypolipidemic effect was the result of up-regulation of LDLR
mRNA and protein expression (Zhou et al., 2014). Coptisine
treatment also resulted in increased expression of LDLR, and
additionally was associated with up-regulated expression of
cholesterol 7-alpha-hydroxylase (CYP7A1) and down-regulated
expression of HMGCR (Chen et al., 2015; He et al., 2015b).
In addition to up-regulated expression of LDLR and CYP7A1,
treatment with palmatine and epiberberine also caused down-
regulation of apical sodium-dependent bile salt transporter
(ASBT) mRNA and protein expression, as well as enhanced
fecal excretion of TC and total bile acids (Ning et al., 2015;
Zou et al., 2016). Jatrorrhizine has been linked to up-regulated
mRNA and protein expression of LDLR and CYP7A1 but it
has no effect on the expression of ASBT and HMGCR (Wu
et al., 2014a). Comparative studies have been done on the lipid-
lowering effect of individual alkaloids and among those tested,
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coptisine was reported to have the highest lipid-lowering effect
(Wu et al., 2014c). More recently, research involving combined
treatment with the alkaloids in RC extract has also been carried
out. While each of the compounds administered in isolation
did demonstrate lipid-lowering effect, the administration of a
combination of these alkaloids resulted in synergistic effects, with
combination therapy resulting in a significantly greater lipid-
lowering effect compared to treatment with a single alkaloid. The
mainmechanisms associated with this effect are thought to be the
retardation of cholesterol synthesis and accelerated clearance of
cholesterol (He et al., 2015a; Kou et al., 2016).
Type 2 diabetes is strongly associated with significant
morbidity and mortality due to cardiovascular complications.
This is in part due to the impaired utilization of carbohydrate
that is part of the metabolic profile of diabetes, which results
in accelerated lipolysis and thus hyperlipidemia or dyslipidemia
(Vijayaraghavan, 2010; Ma et al., 2016). RC has been shown
to have the ability to attenuate the impaired lipid metabolism
associated with diabetes. JiuHuangLian (RC steamed with rice
wine), a traditional Chinese medicine preparation has been
reported to restore the disordered lipid metabolism of type 2
diabetic rats, by decreasing the TC, total glyceride and free fatty
acid levels (Li et al., 2013). The anti-hyperlipidemic effect of the
alkaloids isolated from RC have been further tested on diabetic
mice. Palmatine and jatrorrhizine were shown to decrease the
concentrations of serum TC and triglyceride; while elevated
HDL cholesterol levels were found in diabetic mice administered
with palmatine, jatrorrhizine and berberine (Ma et al., 2016). In
another study, there were decreased serum TC, triglyceride, LDL
cholesterol and increased HDL cholesterol in diabetic rats treated
with berberine (Tang et al., 2006), showing the ability of RC to
attenuate the impaired lipid metabolism in diabetic conditions.
In short, RC has remarkable lipid-lowering effects, mainly
through inhibition of cholesterol synthesis, in combination with
increased usage and excretion of cholesterol.
Anti-Obesity Effect
Obesity has become a global epidemic and is strongly associated
with occurrence of CVDs including heart failure, CHD, sudden
cardiac death and atrial fibrillation (Lavie et al., 2009). As the
condition is characterized by accumulation of extra body fat into
adipocytes, the typical feature of obesity is an increase in the
number and size of adipocytes. The etiology of obesity is rooted
in the process of differentiation of preadipocytes into adipocytes,
known as adipogenesis (Kwak et al., 2013; Choi et al., 2014). The
key transcription regulator genes involved in adipogenesis are
PPAR-γ and CCAAT/enhancer binding protein alpha (C/EBP-
α). The inhibition of these two transcription factors could
represent an effective method of inhibiting adipogenesis (Choi
et al., 2014). RC has potential as an anti-obesity agent as the
extract of RC as well as its isolated alkaloids have demonstrated
the ability to inhibit cellular triglyceride accumulation in 3T3-L1
adipocytes. Significant down-regulation of expression of PPAR-
γ and C/EBP-α by the alkaloids was also demonstrated, which is
consistent with the reported mechanism for the anti-adipogenic
activity of berberine (Huang et al., 2006).
The anti-obesity potential of RC has also been demonstrated
in in vivo studies. The administration of RC and berberine
to mice fed a high fat diet has resulted in significantly lower
body and visceral adipose weight. Interestingly, this effect has
been related to the antimicrobial activities of both RC and
berberine; with reduced fecal microbes resulting in decreased
degradation of dietary polysaccharides, lower calorie intake
and de novo lipogenesis. This was followed by activation of
fasting-induced adipose factor (Fiaf) protein and related gene
expressions of mitochondrial energy metabolism such as AMPK,
PGC1α, UCP2, CPT1α, and Hadhb in visceral adipose tissue (Xie
et al., 2011). Recently, the gut microbiota of obese mice treated
with RC alkaloids has been further studied, demonstrating an
increased abundance of microbial species negatively associated
with obesity namely Sporobacter termitidis, Alcaligenes faecalis,
and Akkermansia muciniphila, and a decreased abundance of
the microbial species positively associated with obesity namely
Escherichia coli, Desulfovibrio C21 _c20 and Parabacteroides
distasonis. This indicates the ability of RC to prevent the
development of obesity by restoring the balance of disrupted gut
microflora associated with the obese condition (He et al., 2016).
RC appears to be effective in preventing obesity as it is able to
inhibit adipogenesis and modulate the gut microflora that plays
important role for the development of obesity.
Anti-Hepatic Steatosis Effect
Nonalcoholic fatty liver disease (NAFLD)—a common liver
disease with a disease spectrum ranging from simple steatosis
to steatohepatitis—is regarded as the hepatic manifestation
of metabolic syndrome (Liu and Lu, 2014). Recently, hepatic
steatosis has been identified as one of the associated risk factors
closely related to the morbidity and mortality of CVDs. It has
been reported that patients with NAFLD have higher risk of
getting CHD compared to the general population (Pisto et al.,
2014). There are several possible mechanisms by which hepatic
steatosis may contribute to the risk of CVDs including oxidative
stress, inflammation, dyslipidemia, ischemia reperfusion injury,
visceral fat, low adiponectin, ectopic adipose tissue distribution,
endothelial dysfunction and postprandial dyslipidemia (Liu and
Lu, 2014). In spite of the many advances in modern medicine,
there is as yet no effective treatment of NAFLD (Huang
et al., 2013). Herbal medicine has been an area of interest
for scientists seeking new modalities of treatment of hepatic
steatosis due to the low incidence of side effects and promising
therapeutic benefits (Xiao et al., 2013; Tan et al., 2016). For
example, Jiao Tai Wan, a classic traditional Chinese prescription
consisting of RC and Cortex Cinamomi was able to inhibit
hepatic lipid accumulation in diabetic rats and humans, due
to down-regulation of lipogenic gene expression and inhibition
of lipogenesis in liver tissue (Huang et al., 2013). Sam-Hwang-
Sa-Sim-Tang, a Korean traditional preparation which contains
RC, Scutellaria radix and Rhei rhizoma also exhibited protective
effect against hepatic steatosis by inhibiting the expression of
hepatic molecules that modulate cholesterol metabolism (Ahn
et al., 2013). While RC extract clearly does have significant
potential as an anti-hepatic steatosis agent, there has been interest
in identifying which of the extract’s active components exert
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the greatest anti-hepatic steatosis effect. Using a free fatty-acid
induced hepatic steatosis HepG2 cell assay, Fan et al. (2013)
demonstrated that berberine and coptisine are the alkaloids with
strongest inhibitory effect on triglyceride accumulation. This
is consistent with the findings of other studies that proposed
berberine as the effective compound against hepatic steatosis
(Yuan et al., 2015; Guo et al., 2016; Zhang et al., 2016). In short,
RC possesses anti-hepatic steatosis effect which is related to its
ability to inhibit hepatic lipogenesis.
Protection from Myocardial
Ischemia-Reperfusion Injury
Coronary artery disease resulting in compromised oxygen supply
to the myocardium is a common cause of morbidity and
mortality. Medical intervention now makes it possible to achieve
rapid restoration of blood flow to the ischemic myocardium
following an acute event, which should produce better clinical
outcomes as prompt restoration of blood circulation helps to
prevent further tissue injury. However, the restoration of blood
flow or reperfusion, will also cause injury, which is known
as myocardial ischemia reperfusion injury (I/R) (Yu et al.,
2015). Apoptosis is an important cellular mechanism resulting
in I/R injury, with oxidative stress representing one of the
major contributing factors promoting apoptosis. The excessive
production of ROS which are mainly produced by mitochondria
will initiate apoptotic signaling (Chan et al., 2012, 2015).
Hence, reducing oxidative stress may help inhibit apoptosis thus
potentially providing an effective strategy to attenuate I/R injury
(Fan et al., 2012). Traditional Chinese herbal treatment have
been commonly used to treat MI for hundreds of years and
recently, it has also been reported to exert protective effect against
myocardial I/R injury (Liu et al., 2013; Li et al., 2014; Zhao et al.,
2016a).
One example of the traditional Chinese medications is San-
Huang-Xie-Xin-Tang (SHXT), which consists of three herbs: RC,
Scutellariae radix and Rhei rhizome. Liou et al. (2011) showed
that pre-treatment with SHXT was associated with significantly
lower arrhythmia scores, reduced mortality rates and reduced
levels of cardiac enzymes such as creatine kinase (CK), lactate
dehydrogenase (LDH) and troponin I in rats with myocardial I/R
injury. Additionally, there was reduced infarct size and decreased
apoptosis in myocytes, partly due to modulation of endothelial
nitric oxide synthase (eNOS) and MAPK pathways. While it is
commonly used as a component of herbal mixtures, the extract
of RC alone has been shown to possess cardioprotective effect
against I/R damage. Administration of crude extract of RC for
7 days preceding acute myocardial injury in rats was associated
with reduced myocardial injury as evidenced by decreased ST-
T elevation on electrocardiogram (ECG) and biochemically by
decreased levels of CK and LDH. Other beneficial effects were
reduction in oxidative stress reflected by reduced levels of
malondiealdehyde (MDA) and increased activity of superoxide
dismutase (SOD) (Liu et al., 2010).
Several active compounds identified in RC have been
suggested as possible candidates accounting for the
cardioprotective activities against I/R injury as demonstrated.
One of the compounds that appears to have cardioprotective
activity is berberine. Although the cardioprotective activity of
berberine is well recognized, the exact mechanism by which it
protects from I/R injury remains unknown. Chang et al. (2012)
found that pretreatment with berberine decreased infarct size
and reduced the incidence as well as duration of arrhythmias
in rats with I/R injury with demonstrable difference in AMPK
activity in both non-ischemic areas (NIA) and myocardial areas
at risk (AAR). Up-regulation of AMPK in the NIA helped to
enhance cardiac function through increased uptake of glucose,
glycolysis and oxidation of fatty acid whereas down-regulation
of AMPK in the areas at risk helped to protect the cardiac
myocytes from apoptosis. This protective effect of berberine
was later specifically demonstrated in the CVD prone diabetic
heart, as demonstrated by the regulation of myocardial energy
metabolism by berberine during I/R injury (Chang et al., 2016).
In myocardial I/R, there is always excessive autophagy which
will lead to expansive degradation of cytosolic proteins and
organelles, resulting in collapse of cellular functions. Huang
et al. (2015) have reported the beneficial effect of berberine
in lowering the cellular autophagy level in berberine-treated
myocytes exposed to I/R injury which were found to have
reduced expression of autophagy-related proteins, which
then led to suppression of autophagy activation. Berberine’s
cardioprotective action may also be associated with its anti-
apoptotic action. Based on both in vitro and in vivo results,
berberine decreases I/R-induced myocardial apoptosis, as a
result of modulation of the Notch1/ Hairy and enhancer of
split 1(Hes1)- Phosphatase and tensin homolog deleted on
chromosome 10 (PTEN)/Akt signaling pathway (Yu et al., 2015).
In a diabetic rat model, berberine exerted anti-apoptotic activity
through activation of AMPK and PI3K-Akt-eNOS signaling
(Chen et al., 2014).
Mitochondrial dysfunction is an additional factor believed
to be responsible for myocardial I/R injury. Treatment
with berberine has been shown to improve mitochondrial
dysfunction, as demonstrated by improved mitochondrial
membrane potential, increased mitochondrial complex I activity
and reduced release of cytochrome C from the mitochondria
(Wang et al., 2015). Endoplasmic reticulum (ER) stress is
also known to play an important part during I/R injury.
Unfolded protein response (UPR) is initiated in the myocardium
after I/R and the continuous UPR causes upregulation of
proapoptotic proteins. Consequently, cellular apoptosis occurs,
resulting in myocardial I/R injury (Wu et al., 2014b). The
role of berberine in modulation of ER stress level during
myocardial I/R injury has also been described. Pretreatment
with berberine has resulted in suppressed myocardial I/R
induced ER stress due to the activation of Janus kinase 2/signal
transducer and activator of transcription 3 (JAK2/STAT3)
signaling (Zhao et al., 2016b) An additional mechanism by
which berberine is able to ameliorate myocardial I/R injury is
via repression of the inflammatory response. Lower levels of
inflammatory markers, namely the cytokines tumor necrosis
factor (TNF)-α, IL-6 and IL-β were found in rats pre-treated
with berberine prior to induction of myocardial ischemia; this
was believed to be mediated by downregulation of PI3K/AKT
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signaling thus preventing myocardial I/R injury (Zhu and Li,
2016).
Coptisine is one of the other compounds in RC that
might have a role in prevention of I/R injury. In a rat
model, administration of coptisine alleviated I/R-induced
arrhythmias and attenuated the reduction in ejection fraction
as well as fractional shortening on echocardiography. Treatment
with coptisine was also associated with reduced infarct size,
suppressed myocardial apoptosis and reduced proinflammatory
cytokines. Based on the reduced expression of Rho, Rho-kinase
1 (ROCK1), ROCK2 and attenuation of myosin phosphatase
targeting subunit-1 phosphorylation, it was speculated that
inhibition of the Rho/ROCK pathway was likely to be coptisine’s
mechanism of cardioprotection (Guo et al., 2013).
Palmatine, another component contained in RC extract,
is also recognized as a potential cardioprotective agent. The
administration of palmatine to rats prior to myocardial I/R
injury was associated with reduced I/R–induced myocardial
dysfunction as evidenced by inhibition of the expected increase
in LDH, CK, and MDA, as well as significant reduction in
cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase
(iNOS) expression. Interestingly, in vitro studies using human
aortic endothelial cells resulted in increased heme-oxygenase-
1 induction, indicating the strong antioxidant and anti-
inflammatory action of palmatine (Kim et al., 2009). Based
on the studies, RC is a potential protective agent against
myocardial I/R injury through its active compounds which
exert different protection actions including regulation of cellular
energy metabolism, anti-apoptosis effect, protection against
mitochondrial dysfunction and ER stress as well as antioxidant
and anti-inflammatory action.
CONCLUSION
In conclusion, results of recent studies appear to support for
the usage of RC for treatment of CVDs and related conditions.
They have provided scientific evidence that RC’s use in traditional
Chinese medicine for the last 2000 years was likely to have
truly resulted in desirable effects on CVDs via its effects on
the various risk factors and biochemical pathways involved in
CVDs pathogenesis. RC appears to have tremendous potential
as a cardioprotective agent given its ability to improve a
large number of parameters associated with increased risk of
CVDs including anti-atherosclerotic effect, lipid-lowering effect,
anti-obesity effect and anti-hepatic steatosis effect. Aside from
reducing incidence, it also reduces the damage caused by CVDs
as it confers protection from myocardial I/R injury. These
properties are mainly attributed to its bioactive compounds:
berberine, coptisine, palmatine, epiberberine, jatrorrhizine and
magnoflorine. However, knowledge regarding the underlying
mechanisms of action of these compounds is still limited.
More research investigating the exact mechanisms of RC’s
cardioprotective activities is needed. This is to fully exploit this
traditional remedy’s potential to contribute to the development
of new cardioprotective agents as this could be a new opportunity
to reduce global prevalence of CVDs.
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